Immunexpress.com

Publication in BMC Medicine demonstrates the combination of SeptiCyte® TRIAGE and SeptiCyte® VIRUS can discriminate between bacterial and viral infections in Emergency Department patients SEATTLE, Sept. 23, 2020 /PRNewswire/ — Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, announced today new data in collaboration with researchers at the University College of London. …

Read More
Immunexpress.com

Immunexpress, Inc., a medical diagnostic company focused on improving outcomes for suspected sepsis patients, today announced the presentation of analytical and clinical performance data for SeptiCyte® technology in two posters at the virtual e-ISICEM (International Symposium on Intensive Care and Emergency Medicine), from Sept. 15-18, 2020. The first poster, titled “Clinical Performance of a Rapid Sepsis…

Read More
Immunexpress.com

During this COVID-19 pandemic, ICU doctors have frequently recognized that what they are observing in their severe COVID-19 patients, is in fact sepsis, defined as a life-threatening organ failure caused by a dysregulated immune response caused by infection. As a consequence Immunexpress was awarded a government contract for studies to validate the role of SeptiCyte RAPID…

Read More